Investing.com - Amgen (NASDAQ: AMGN) reported second quarter EPS of $4.97, $0.01 worse than the analyst estimate of $4.98. Revenue for the quarter came in at $8.39B versus the consensus estimate of $8.35B.
Guidance
Amgen sees FY 2024 EPS of $19.10-$20.10 versus the analyst consensus of $17.87.
Amgen sees FY 2024 revenue of $32.80B-$33.80B versus the analyst consensus of $30.30B.
Amgen's stock price closed at $328.95. It is up 6.06% in the last 3 months and up 30.05% in the last 12 months.
Amgen saw 8 positive EPS revisions and 13 negative EPS revisions in the last 90 days. See Amgen's stock price’s past reactions to earnings here.
According to InvestingPro, Amgen's Financial Health score is "good performance".
Check out Amgen's recent earnings performance, and Amgen's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar
Should you invest $2,000 in AMGN right now?
ProPicks AI are 6 model portfolios created by Investing.com which identify the best stocks for investors to buy now. The stocks that made the cut could produce monster returns in the coming years. Is AMGN one of them?
Unlock ProPicks AI to find out